glulisine (Apidra)
Jump to navigation
Jump to search
Introduction
Tradename: Apidra (FDA-approved in 2004)
Indications
Dosage
- can mix with NPH
- draw glulisine into syring 1st, inject immediately
100 units/mL, 10 mL vials, 3 mL cartridge
Pharmacokinetics
- rapid-acting insulin, onset 10-15 minutes
- peak 1-1.5 hours
- duration 3-5 hours Presumptively a recombinant protein.
Notes
Manufacturer: Aventis
More general terms
References
- ↑ Prescriber's Letter 12(2): 2005 New Drugs Approved by the FDA in 2004 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=210216&pb=PRL (subscription needed) http://www.prescribersletter.com
- ↑ Prescriber's Letter 13(3): 2006 Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220309&pb=PRL Comparison of Insulins (subscription needed) http://www.prescribersletter.com